Deprescribing interventions for gabapentinoids in adults: A scoping review.
deprescribe
gabapentin
gabapentinoid
intervention
pregabalin
taper
withdraw
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
08
03
2023
received:
14
12
2022
accepted:
03
05
2023
medline:
16
8
2023
pubmed:
24
5
2023
entrez:
23
5
2023
Statut:
ppublish
Résumé
The emerging issue of rising gabapentinoid misuse is being recognized alongside the lack of current evidence supporting the safe and effective deprescribing of gabapentinoids. This scoping review aimed to assess the extent and nature of gabapentinoid deprescribing interventions in adults, either in reducing dosages, or prescribing of, gabapentinoids. Electronic databases were searched on 23 February 2022 without restrictions. Eligible studies included randomized, non-randomized and observational studies that assessed an intervention aimed at reducing/ceasing the prescription/use of a gabapentinoid in adults for any indication in a clinical setting. The research outcomes investigated the type of intervention, prescribing rates, cessations, patient outcomes and adverse events. Extracted outcome data were categorized as either short (≤3 months), intermediate (>3 but <12 months) or long (≥12 months) term. A narrative synthesis was conducted. The four included studies were conducted in primary and acute care settings. Interventions were of dose-reducing protocols, education and/or pharmacological-based approaches. In the randomized trials, gabapentinoid use could be ceased in at least one third of participants. In the two observational trials, gabapentinoid prescribing rates decreased by 9%. Serious adverse events and adverse events specifically related to gabapentinoids were reported in one trial. No study included patient-focused psychological interventions in the deprescribing process, nor provided any long-term follow-up. This review highlights the lack of existing evidence in this area. Due to limited available data, our review was unable to make any firm judgements on the most effective gabapentinoid deprescribing interventions in adults, highlighting the need for more research in this area.
Substances chimiques
Gabapentin
6CW7F3G59X
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2677-2690Informations de copyright
© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Pfizer. Lyrica prescribing information; 2018. Accessed March 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf
Pfizer. Neurotin prescribing information; 2017. Accessed March 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
Therapeutic Goods Administration. Lyrica (pregabalin) Product and Consumer Medicine Information Licence; 2021. Accessed March 7, 2023. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-CMI-05617-3
Therapeutic Goods Administration. Neurontin (gabapentin) Product and Consumer Medicine Information Licence; 2021. Accessed March 7, 2023. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-CMI-04869-3
Goodman CW, Brett AS. Gabapentin and pregabalin for pain-is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411-414. doi:10.1056/NEJMp1704633
Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ. Gabapentinoid pharmacology in the context of emerging misuse liability. J Clin Pharmacol. 2021;61(Suppl 2):S89-S99. doi:10.1002/jcph.1833
Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study. BJGP Open. 2021;5(1):bjgpopen20X101120. doi:10.3399/bjgpopen20X101120
Finnerup NBMD, Attal NP, Haroutounian SP, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0
Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99(3):557-566. doi:10.1016/S0304-3959(02)00255-5
Yu X, Liu T, Zhao D, et al. Efficacy and safety of pregabalin in neuropathic pain followed spinal cord injury: a review and meta-analysis of randomized controlled trials. Clin J Pain. 2019;35(3):272-278. doi:10.1097/AJP.0000000000000675
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179(5):695-701. doi:10.1001/jamainternmed.2019.0086
Mathieson S, Valenti L, Maher CG, et al. Worsening trends in analgesics recommended for spinal pain in primary care. Eur Spine J. 2018;27(5):1136-1145. doi:10.1007/s00586-017-5178-4
Mathieson S, Lin CC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ. 2020;369:m1315. doi:10.1136/bmj.m1315
Enke O, New HA, New CH, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ. 2018;190(26):E786-E793. doi:10.1503/cmaj.171333
Mathieson S, Maher CG, McLachlan AJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376(12):1111-1120. doi:10.1056/NEJMoa1614292
Zhou L, Bhattacharjee S, Kwoh CK, et al. Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016. J Clin Med. 2019;9(1):83. doi:10.3390/jcm9010083
Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. Signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66(9):947-953. doi:10.1007/s00228-010-0853-y
Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69(6):1335-1342. doi:10.1007/s00228-012-1464-6
Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction. 2019;114(6):1026-1034. doi:10.1111/add.14412
Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials: meta-analysis of pregabalin adverse effects. Epilepsia. 2011;52(4):826-836. doi:10.1111/j.1528-1167.2010.02966.x
Kriikku P, Ojanperä I. Pregabalin and gabapentin in non-opioid poisoning deaths. Forensic Sci Int. 2021;324:110830. doi:10.1016/j.forsciint.2021.110830
Oh GY, Moga DC, Abner EL. Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer's Coordinating Center (2006-2019). Br J Clin Pharmacol. 2023;89(1):410-415. doi:10.1111/bcp.15532
Peltokorpi J, Hakko H, Riipinen P, Riala K. Profile of substance misuse among adolescent and young adult gabapentinoid users: a register-based follow-up study of former adolescent psychiatric inpatients. Subst Use Misuse. 2021;56(5):598-605. doi:10.1080/10826084.2021.1883662
Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019;365:l2147. doi:10.1136/bmj.l2147
McAnally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther. 2020;9(2):441-452. doi:10.1007/s40122-020-00189-x
Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-426. doi:10.1007/s40265-017-0700-x
Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-834. doi:10.1001/jamainternmed.2015.0324
Jansen J, Naganathan V, Carter SM, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893. doi:10.1136/bmj.i2893
Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharmacol. 2019;41(1):167-178. doi:10.1007/s11096-019-00784-9
Gannon JM, Lupu A, Brar J, et al. Deprescribing anticholinergic medication in the community mental health setting: a quality improvement initiative. Res Social Adm Pharm. 2021;17(10):1841-1846. doi:10.1016/j.sapharm.2020.12.010
Sawan MJ, Moga DC, Ma MJ, Ng JC, Johnell K, Gnjidic D. The value of deprescribing in older adults with dementia: a narrative review. Expert Rev Clin Pharmacol. 2021;14(11):1367-1382. doi:10.1080/17512433.2021.1961576
Mathieson S, Maher CG, Ferreira GE, et al. Deprescribing opioids in chronic non-cancer pain: systematic review of randomised trials. Drugs. 2020;80(15):1563-1576. doi:10.1007/s40265-020-01368-y
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-473. doi:10.7326/M18-0850
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
Collinson MJ. Reducing medication-related harm from gabapentinoids in primary care: a quality improvement project with a completed pdsa cycle. Age and Ageing: British Geriatrics Society Communications to the Spring Meeting Cardiff United Kingdom. 2019;48:ii1-ii10. doi:10.1093/ageing/afz055.33
Chazot P, Johnson L, Hampshire K, Kinchin B, Cole F. Gabapentinoids and opioids tapering tool box (GOTT): midtrial evaluation. Br J Clin Pharmacol. 2021;87(12):4884-4885. doi:10.1111/bcp.15025
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
McDonald EG, Wu PE, Rashidi B, et al. The MedSafer study-electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Intern Med. 2022;182(3):265-273. doi:10.1001/jamainternmed.2021.7429
Kasper S, Iglesias-Garcia C, Schweizer E, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014;17(5):685-695. doi:10.1017/S1461145713001557
National Institute for Health and Care Excellence (NICE). Exceptional surveillance of neuropathic pain in adults: pharmacological management in non-specialist settings. (NICE guideline CG173); 2019.
Doherty AJ, Boland P, Reed J, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 2020;4(3):bjgpopen20X101096. doi:10.3399/bjgpopen20X101096
Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;CD007938. doi:10.1002/14651858.CD007938.pub4
Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;CD011790. doi:10.1002/14651858.CD011790.pub2
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;CD007076. doi:10.1002/14651858.CD007076.pub3
Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30(1):9-25. doi:10.1007/s40263-015-0303-6
Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatry Q. 2016;87(4):763-767. doi:10.1007/s11126-016-9421-7
Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol. 2017;73(8):927-935. doi:10.1007/s00228-017-2257-8
Niznik JD, Collins BJ, Armistead LT, et al. Pharmacist interventions to deprescribe opioids and benzodiazepines in older adults: a rapid review. Res Social Adm Pharm. 2022;18(6):2913-2921. doi:10.1016/j.sapharm.2021.07.012
Chen C, Winterstein AG, Lo-Ciganic W-H, Tighe PJ, Wei Y-JJ. Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: a population-based cohort study. PLoS Med. 2022;19(3):e1003921. doi:10.1371/journal.pmed.1003921
National Institute for Health and Care Excellence (NICE). Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NICE guideline [NG215]); 2022.
Ng BJ, Le Couteur DG, Hilmer SN. Deprescribing benzodiazepines in older patients: impact of interventions targeting physicians, pharmacists, and patients. Drugs Aging. 2018;35(6):493-521. doi:10.1007/s40266-018-0544-4
Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. J Consult Clin Psychol. 2014;82(3):448-459. doi:10.1037/a0035798
Zheng Z, Gibson S, Helme RD, et al. Effects of electroacupuncture on opioid consumption in patients with chronic musculoskeletal pain: a multicenter randomized controlled trial. Pain Med. 2019;20(2):397-410. doi:10.1093/pm/pny113